Pfizer Inc on Tuesday raised its forecast for full-year sales of the COVID-19 vaccine it co-developed with Germany's BioNTech SE, as a vaccination drive across the globe intensifies. The U.S. drugmaker now expects full-year sales of $26 billion from the vaccine, up from its prior forecast of about $15 billion.
- The United States is expected to authorize the Pfizer-BioNTech Covid-19 vaccine for children age 12 and up by early next week, US media reported Monday.
pfizer has applied for emergency use authorization for its Covid vaccine for children and teenagers between ages 12 and 15, according to CNN, citing a government official.
"The FDA will have to amend the emergency use authorization for the vaccine, but the process should be straightforward," CNN reported.
The US Food and Drug Administration is expected to grant that approval by early next week. After the FDA decision, the Centers for Disease Control and Prevention advisory committee will meet to recommend how the vaccine should be used.
A spokeswoman for the FDA declined to give details on the approval timeline, telling The Washington Post: "We are working to review this request as quickly and transparently as possible."
The pfizer vaccine is currently authorized for people 16 and older in the United States.